These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37420173)

  • 1. EFEMP2 upregulates PD-L1 expression via EGFR/ERK1/2/c-Jun signaling to promote the invasion of ovarian cancer cells.
    Shen X; Jin X; Fang S; Chen J
    Cell Mol Biol Lett; 2023 Jul; 28(1):53. PubMed ID: 37420173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 3. Glutamine Deprivation Induces PD-L1 Expression via Activation of EGFR/ERK/c-Jun Signaling in Renal Cancer.
    Ma G; Liang Y; Chen Y; Wang L; Li D; Liang Z; Wang X; Tian D; Yang X; Niu H
    Mol Cancer Res; 2020 Feb; 18(2):324-339. PubMed ID: 31672701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiotherapy Upregulates Programmed Death Ligand-1 through the Pathways Downstream of Epidermal Growth Factor Receptor in Glioma.
    Song X; Shao Y; Jiang T; Ding Y; Xu B; Zheng X; Wang Q; Chen X; Gu W; Wu C; Jiang J
    EBioMedicine; 2018 Feb; 28():105-113. PubMed ID: 29396299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-JUN/VEGFR2 signaling axis in ovarian cancer.
    Yang Y; Xia L; Wu Y; Zhou H; Chen X; Li H; Xu M; Qi Z; Wang Z; Sun H; Cheng X
    Cancer Commun (Lond); 2021 Jun; 41(6):511-527. PubMed ID: 33939321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DRD1 suppresses cell proliferation and reduces EGFR activation and PD-L1 expression in NSCLC.
    Grant CE; Flis AL; Toulabi L; Zingone A; Rossi E; Aploks K; Sheppard H; Ryan BM
    Mol Oncol; 2024 Jun; 18(6):1631-1648. PubMed ID: 38572507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer.
    Zhang GQ; Jiao Q; Shen CT; Song HJ; Zhang HZ; Qiu ZL; Luo QY
    Cancer Sci; 2021 Mar; 112(3):997-1010. PubMed ID: 33247999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
    Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
    J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers.
    Cheng CC; Lin HC; Tsai KJ; Chiang YW; Lim KH; Chen CG; Su YW; Peng CL; Ho AS; Huang L; Chang YC; Lin HC; Chang J; Chang YF
    Mol Carcinog; 2018 Nov; 57(11):1588-1598. PubMed ID: 30035369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer.
    Yu W; Hua Y; Qiu H; Hao J; Zou K; Li Z; Hu S; Guo P; Chen M; Sui S; Xiong Y; Li F; Lu J; Guo W; Luo G; Deng W
    Cell Death Dis; 2020 Jul; 11(7):506. PubMed ID: 32632098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC.
    Jiang L; Guo F; Liu X; Li X; Qin Q; Shu P; Li Y; Wang Y
    Sci Rep; 2019 Mar; 9(1):3705. PubMed ID: 30842489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EFEMP2 increases the invasion ability of cervical cancer cells by promoting EMT via the Raf/MEK/ERK signaling pathway.
    Li N; Ji GX; Yang ZY
    Neoplasma; 2022 Sep; 69(5):1185-1197. PubMed ID: 36004647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
    Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
    Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpressed ITGA2 promotes malignant tumor aggression by up-regulating PD-L1 expression through the activation of the STAT3 signaling pathway.
    Ren D; Zhao J; Sun Y; Li D; Meng Z; Wang B; Fan P; Liu Z; Jin X; Wu H
    J Exp Clin Cancer Res; 2019 Dec; 38(1):485. PubMed ID: 31818309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma.
    Han K; Zhang Y
    J Cancer Res Ther; 2019; 15(4):914-920. PubMed ID: 31436252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 14-3-3σ protein promotes HCC anoikis resistance by inhibiting EGFR degradation and thereby activating the EGFR-dependent ERK1/2 signaling pathway.
    Song J; Liu Y; Liu F; Zhang L; Li G; Yuan C; Yu C; Lu X; Liu Q; Chen X; Liang H; Ding Z; Zhang B
    Theranostics; 2021; 11(3):996-1015. PubMed ID: 33391517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
    Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
    Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Krill oil extract inhibits the migration of human colorectal cancer cells and down-regulates EGFR signalling and PD-L1 expression.
    Jayathilake AG; Veale MF; Luwor RB; Nurgali K; Su XQ
    BMC Complement Med Ther; 2020 Dec; 20(1):372. PubMed ID: 33287803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumoral Delivery of an Adenoviral Vector Carrying the
    Nakagawa S; Serada S; Kakubari R; Hiramatsu K; Sugase T; Matsuzaki S; Matsuzaki S; Ueda Y; Yoshino K; Ohkawara T; Fujimoto M; Kishimoto T; Kimura T; Naka T
    Mol Cancer Ther; 2018 Sep; 17(9):1941-1950. PubMed ID: 29891489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-7 inhibits tumor metastasis and reverses epithelial-mesenchymal transition through AKT/ERK1/2 inactivation by targeting EGFR in epithelial ovarian cancer.
    Zhou X; Hu Y; Dai L; Wang Y; Zhou J; Wang W; Di W; Qiu L
    PLoS One; 2014; 9(5):e96718. PubMed ID: 24816687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.